1-2 of 2
David Taussig
Close
Sort by
Journal Articles

Venetoclax–based low intensity therapy in molecular failure of NPM1 -mutated AML

Clinical Trials & Observations
Carlos Jimenez-Chillon, Jad Othman, David Taussig, Carlos Jimenez-Vicente, Alexandra Martinez-Roca, Ing Soo Tiong, Manish Jain, James Aries, Seda Cakmak, Steven Knapper, Daniel Tuyet Kristensen, Vidhya Murthy, Joy Zacharoula Galani, Charlotte Kallmeyer, Loretta Ngu, David Veale, Simon Bolam, Nina Orfali, Anne Parker, Cara Manson, Jane Parker, Thomas Erblich, Deborah Richardson, Katya Mokretar, Nicola Potter, Ulrik Malthe Overgaard, Anne Stidsholt Roug, Andrew H. Wei, Jordi Esteve, Martin Jädersten, Nigel Russell, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (2): 343–352.
https://doi.org/10.1182/bloodadvances.2023011106
Published: 2024
Includes: Supplemental data
Journal Articles

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Clinical Trials & Observations
Marina Y. Konopleva, Christoph Röllig, Jamie Cavenagh, Dries Deeren, Larisa Girshova, Jürgen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas A. Schäfer, Oliver Ottmann, Mario Petrini, Arnaud Pigneux, Alessandro Rambaldi, Christian Recher, Rebeca Rodriguez-Veiga, David Taussig, Norbert Vey, Sung-Soo Yoon, Marion Ott, Susanne Muehlbauer, Benjamin M. Beckermann, Olivier Catalani, Magali Genevray, Kirsten Mundt, Candice Jamois, Pierre Fenaux, Andrew H. Wei
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4147–4156.
https://doi.org/10.1182/bloodadvances.2021006303
Published: 2022
Includes: Supplemental data